TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04821063
Drug: ITF2357 10 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
Study: NCT04821063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 20 mL; Dosage form: suspension; Route of administration: oral
Study: NCT04821063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 30 mL; Dosage form: suspension; Route of administration: oral
Study: NCT05671081
Drug: Narcotic Analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
Study: NCT05023681
Drug: Recombinant Staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT05023681
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT05607537
Drug: E7386 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7386 40 mg tablet.
Study: NCT05877313
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
Study: NCT05963867
Drug: [89Zr]Zr-BI 764532
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[89Zr\]Zr-BI 764532
Study: NCT05832580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in similar capsules
Study: NCT05657015
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.2% of SMV in situ gel at baseline
Study: NCT06313463
Drug: Carrellizumab + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total
Study: NCT06313463
Drug: Placebo + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
Study: NCT04979650
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g of normal saline without methylprednisolone succinate
Study: NCT05081388
Drug: REGN14256
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-cutaneous (SC) single dose
Study: NCT05081388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC single dose
Study: NCT02658292
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
Study: NCT06291077
Drug: anticalcineurins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keeping of anticalcineurins
Study: NCT06079541
Drug: Placebo in Cohorts 1 to 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral once
Study: NCT06079541
Drug: Placebo in 3 Cohorts
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral once
Study: NCT05529147
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants receive antihypertensive drug treatment as part of regular care to induce systolic BP (SBP) reductions ≥10 mmHg within 6-8 weeks, while reaching a treatment target of ≤140 mmHg, and while preserving diastolic BP ≥70 mmHg.
Study: NCT04436081
Drug: THC-free CBD Oil
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp-based CBD oil Gelcaps
Study: NCT04436081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Gelcaps
Study: NCT05092360
Drug: Pegylated Liposomal Doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
Study: NCT06492941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was human blood albumin without the active ingredient docetaxel
Study: NCT06492941
Drug: Best supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
Study: NCT05470413
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 4 mg
Study: NCT05470413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05209074
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
Study: NCT05107778
Drug: ASC42 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC42 10mg orally once daily;
Study: NCT05107778
Drug: ASC42 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC42 15mg orally once daily.
Study: NCT05107778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily.
Study: NCT04780438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients rendomized in this arm will receive placebo.
Study: NCT06008327
Drug: Topical 15% Trichloroacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
Study: NCT05790330
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As per usual standard of care
Study: NCT05934097
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 intravenously
Study: NCT05934097
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 intravenously
Study: NCT04472000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
Study: NCT05951296
Drug: Leramistat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Leramistat
Study: NCT05951296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05003440
Drug: NNC0385-0434
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
Study: NCT05428930
Drug: CKDB-501B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection CKDB-501B
Study: NCT05428930
Drug: Botox®50U
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection Botox®50U
Study: NCT06253598
Drug: Recombinant Human Adenovirus Type 5
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Adenovirus Type 5( H101 )was administered intratumorally on day 1 and 5 of cycle 1 and cycle 2. If the sum of the maximum diameters of the lesions was less than or equal to 10 cm, the total dose was 1.0×10\^12 vp . If the sum of the maximum diameters of the lesions was more than 10 cm, the total dose was 1.5×10\^12 vp. Recombinant Human Adenovirus Type 5 was diluted to 30% of the total tumor volume with normal saline before administration. Under the guidance of ultrasound, percutaneous puncture was performed to the center of the tumor, and the solution was uniformly injected into the tumor. If there are multiple lesions, the distribution of each lesion should be proportional to the size of the tumor. No more than 5 lesions.
Study: NCT06207955
Drug: TMJ Arthrocentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMJ Arthrocentesis By Saline
Study: NCT06610734
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT06609551
Drug: XELOX intensive treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX intensive treatment group. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
Study: NCT04834024
Drug: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
Study: NCT06116955
Drug: Midazolam and sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
Study: NCT06116955
Drug: Midazolam, sufentanil and propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
Study: NCT06116955
Drug: Remazolam and sufentanil.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
Study: NCT06116955
Drug: Remazolam, sufentanil and propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
Study: NCT05740280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for intravenous injection
Study: NCT06417567
Drug: NEPA
Normalized name: cinepazet
DrugBank: Cinepazet (DB13342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
Study: NCT05184088
Drug: [18F]florbetaben
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled patients will undergo \[18F\]florbetaben PET imaging.
Study: NCT05586074
Drug: Clifutinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral
Study: NCT05586074
Drug: Ara-C±IDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC and IV
Study: NCT05586074
Drug: FLAG-IDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC and IV
Study: NCT05892237
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
Study: NCT04700332
Drug: DCFPyL PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate Membrane Specific Antigen-specific imaging
Study: NCT05665465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered placebo nasal spray and provide subjective reactions
Study: NCT06526208
Drug: MB-IMP
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.
Study: NCT05984004
Drug: 0.9% NaCl isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
Study: NCT05018221
Drug: Placebo capsule (Vitamin K1)
Normalized name: vitamin K1 Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered 3 times per week following the subject's hemodialysis session.
Study: NCT05610332
Drug: FLOT scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w
Study: NCT05397938
Drug: JMT103 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
Study: NCT05846347
Drug: GC012F injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
Study: NCT04928430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion
Study: NCT05186194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04976127
Drug: Talineuren
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
Study: NCT04952259
Drug: Shexiang Tongxin Dropping Pills + routine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral+percutaneous coronary intervention
Study: NCT06396390
Drug: Progestin
Normalized name: Progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
Study: NCT06566482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
Study: NCT06243393
Drug: Physicians Choice (PhC).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to oncologic guidelines.
Study: NCT06042985
Drug: The absorption effect between calcium citrate and calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
Study: NCT05970679
Drug: DW1125 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Atorvastatin 10/5 mg placebo
Study: NCT05970679
Drug: DW1125A placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5mg placebo
Study: NCT05970679
Drug: DW1125E placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg placebo
Study: NCT05970679
Drug: DW1125A-1 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10mg placebo
Study: NCT06098456
Drug: EGCG, FA, HA, B12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
Study: NCT05816265
Drug: IV Iron Infusion Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
Study: NCT05931263
Drug: C-BEAM Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidemide，carmustine, etoposide, cytarabine, and melphalan
Study: NCT05931263
Drug: BEAM Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: carmustine, etoposide, cytarabine, and melphalan
Study: NCT05502549
Drug: CB03-154
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB03-154 tablet once daily.
Study: NCT05502549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily.
Study: NCT06044103
Drug: PDB + PCS
Normalized name: aspirin / caffeine / propoxyphene hydrochloride Oral Capsule [PC-CAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
Study: NCT05045508
Drug: OC-01 (varenicline 0.6mg/ml) nasal spray
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
Study: NCT05045508
Drug: Placebo (vehicle) Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) nasal spray \[control\]
Study: NCT05621161
Drug: Postoperative analgesia management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
Study: NCT05143463
Drug: NS101 IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
Study: NCT05966233
Drug: R-DHAP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1
Study: NCT05966233
Drug: Pola-R-DHAP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Polatuzumab Vedotin 1.8 mg/kg IV on D1~* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1
Study: NCT06372678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00032526
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05545475
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study: NCT05063253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, SC, once weekly
Study: NCT06277128
Drug: WS016 3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.
Study: NCT06277128
Drug: WS016 6g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.
Study: NCT06277128
Drug: WS016 12g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.
Study: NCT06277128
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
Study: NCT05799053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing microcrystalline cellulose
Study: NCT05867563
Drug: TQB2103 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2. The drug structure mainly includes anti-humanized CLDN 18.2 antibody, linker and cytotoxic DDDXD, with Drug antibody Ratio (DAR) of 8.
Study: NCT05672563
Drug: Saline infusion sonography for evaluation of cesarean scar
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
Study: NCT06071416
Drug: Biphasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: appliaction of BCP bone substitute
Study: NCT04957901
Drug: modified BFM-95 protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical stage system, risk stratification and treatment for pediatric mature B-NHL were according to the modified BFM-95 protocol. The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
Study: NCT04861142
Drug: Anti-osteoporotic medication( alendronate or denosumab)
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of anti-osteoporotic medication (alendronate or denosumab)